New combo aims to boost remission in rare lymphoma
NCT ID NCT06510309
First seen Mar 13, 2026 · Last updated Jun 21, 2026 · Updated 14 times
Summary
This phase 2 study is testing whether combining rituximab (an antibody) with venetoclax (a targeted pill) can improve outcomes for people with untreated marginal zone lymphoma. About 33 participants will receive the combination, and researchers will measure how many achieve a complete response. The goal is to find a more effective frontline therapy for this slow-growing blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab and venetoclax
What this could lead to
If successful, this combination could offer a more effective first-line treatment for marginal zone lymphoma, potentially leading to higher remission rates.
What could go wrong
This is a small, early-phase trial with only 33 participants. The treatment may not work better than standard options, and side effects like low blood counts or infections are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.